Kyverna Surges 26% on Stiff Person Syndrome Trial Win
KYTX stock jumps after miv-cel shows statistically significant improvements in registrational SPS trial. 81% of patients exceeded clinically meaningful thresholds.
Kyverna Therapeutics had the kind of morning that changes a company's trajectory.
Shares of the cell therapy developer surged 26% in premarket trading after the company reported positive results from its registrational trial of miv-cel in stiff person syndrome. The data wasn't just good—it was submission-quality.
In the KYSA-8 trial, a single dose of miv-cel delivered rapid, statistically significant improvements across every primary and secondary endpoint at 16 weeks. For a rare disease with no approved treatments, that's the kind of outcome that moves drugs toward approval.
The Numbers
The headline metric: patients showed a median 46% improvement in timed 25-foot walk tests compared to baseline. That's not a marginal gain—it's the difference between needing a walker and walking independently.
| Endpoint | Result | P-value |
|---|---|---|
| Timed 25-foot walk | +46% improvement | 0.0002 |
| Clinically meaningful improvement | 81% of patients | — |
| Walking aid elimination | 67% no longer needed | — |
| Ongoing immunotherapy | 100% discontinued | — |
Of 26 patients dosed, 81% exceeded the clinically meaningful threshold of 20% T25FW improvement. Two-thirds of patients who entered the trial using walking aids no longer needed them by week 16.
Perhaps most importantly: every patient was able to discontinue ongoing immunotherapy. Stiff person syndrome typically requires lifelong treatment with immunosuppressants that carry significant side effects. A single miv-cel infusion replaced that.
What Is Stiff Person Syndrome?
SPS is a rare autoimmune neurological disorder affecting roughly one in a million people. Patients experience progressive muscle stiffness and spasms, eventually losing the ability to walk. The condition is debilitating, and current treatments only manage symptoms.
The disease gained public attention when Celine Dion disclosed her SPS diagnosis in 2022. There are no FDA-approved therapies specifically for SPS.
Miv-cel is a CAR-T cell therapy designed to eliminate the autoreactive B cells that drive autoimmune conditions. The approach has shown promise across multiple indications—Kyverna also reported positive longer-term data in generalized myasthenia gravis at the American Academy of Neurology meeting this week.
The Regulatory Path
These results are from a registrational trial, meaning they're intended to support FDA approval. Kyverna hasn't announced a filing timeline, but the data appear sufficient for a biologics license application.
For a company valued around $1 billion before today's move, an approved therapy in SPS would represent a meaningful commercial opportunity. The rare disease premium pricing model, combined with the lack of competition, creates attractive unit economics.
The question becomes manufacturing and distribution. CAR-T therapies require individualized production for each patient—a logistics challenge that has constrained other cell therapy companies.
The Broader CAR-T Picture
Kyverna's approach extends the CAR-T paradigm beyond oncology into autoimmune disease. Early results from Bristol Myers Squibb's CAR-T programs in lupus generated excitement last year. Kyverna's SPS data adds another proof point.
The autoimmune CAR-T space is getting crowded. Larger players are watching. If Kyverna can demonstrate durable responses and manageable manufacturing, the company becomes an acquisition target.
For now, today's move reflects genuine clinical achievement. An 81% response rate with functional improvement isn't a statistical artifact—it's patients regaining mobility they'd lost.
Biotech rarely delivers clean wins. This is one of them.